Wegovy SELECT

The primary endpoint was time to first occurrence of major adverse cardiovascular events, defined as a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, which occurred in 6.5% of patients treated with semaglutide vs 8.0% of patients with placebo. Hazard ratio 0.80, 95% confidence interval, 0.72-0.90, p<0.001.^1,4

BMI, body mass index; CV, cardiovascular; CVD, cardiovascular disease; HbA_1c, haemoglobin A_1c; MACE, major adverse cardiovascular events; MI, myocardial infarction; PAD, peripheral arterial disease.

^*Defined as having died or attended the final trial list.
^†Defined as intermittent claudication with ankle-brachial index <0.85 (at rest) or peripheral arterial revascularisation procedure or amputation due to atherosclerotic disease.

^‡Standard of care was defined as interventions for managing cardiovascular risk factors, including medical treatment and healthy lifestyle counselling.

^§Primary analysis designed to test for superiority of Wegovy^® relative to placebo for time to first MACE.

Confirmatory secondary endpoints: CV death, composite heart failure endpoint, and all-cause death^1,4

Event incidence: 2.5% Wegovy^®, (n=233 of 8,803) vs 3.0% placebo (n=262 of 8,801). First in testing hierarchy; superiority not achieved.^*

Event incidence: 3.4% Wegovy^®, (n=300 of 8,803) vs 4.1% placebo (n=361 of 8,801)
Superiority testing not performed^†

Event incidence: 4.3% Wegovy^®, (n=375 of 8,803) vs 5.2% placebo (n=458 of 8,801).
Superiority testing not performed^†

^*For CV death endpoint, nominal significance level needed for superiority was 0.023.¹
^†Because the first confirmatory secondary endpoint did not meet the required p-value for hierarchical testing, superiority testing was not performed.⁴

CI, confidence interval; CV, cardiovascular; HF, heart failure.
CV death includes both cardiovascular death and undetermined cause of death.
Composite HF was composed of HF hospitalisation, urgent HF visit, or CV death.
All-cause death was defined as death from any cause.

GLP-1, glucagon-like peptide-1; HCP, healthcare professional.
^*Semaglutide clinical data include patients enrolled in trials for type 2 diabetes, weight management, and cardiovascular-related indications.
^†The effect of Wegovy^® was studied in animal models.
^‡The impact of Wegovy^® on the brain is not fully understood.

Wegovy^® [summary of product characteristics]. Bagsværd, Denmark: Novo Nordisk A/S; 2024.

Vrints C, Adreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes ofthe European Society of Cardiology (ESC). Eur Heart J. Published online 30 August 2024. doi.org/10.1093/eurheartj/ehae177.

Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091.

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232.

Pi-Sunyer X. The Look AHEAD trial: a review and discussion of its outcomes. Curr Nutr Rep. 2014;3(4):387- 391.

James WPT, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905-917.

Topol EJ, Bousser MG, Fox KAA, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet. 2010; 376(9740):517-523.

Nissen SE, Wolski K, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016; 315(10):990-1004.

Bohula EA, Wiviott SD, McGuire DK, et al. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med. 2018;379(12):1107-1117.

10.

Naltrexone/Bupropion Cardiovascular Outcomes Study. ClinicalTrials.gov identifier: NCT02638129. Updated February 27, 2017. Accessed May 30, 2024. https://clinicaltrials.gov/study/NCT02638129

11.

Data on file. Novo Nordisk A/S; Bagsværd, Denmark.

The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown are models and not real patients.

HQ24SEMO00109, September 2024

For healthcare professionals only